Rab7 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RAB7 (RAB7, Member RAS Oncogene Family), also known as RAB7A, is a small GTPase that regulates late endosomal and lysosomal trafficking. It is essential for the maturation of late endosomes, lysosomal fusion, and autophagosome-lysosome fusion. RAB7 dysfunction is implicated in neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's disease.
RAB7 is a ~205 amino acid small GTPase:
- GTP-binding domain: Switch I and Switch II regions for nucleotide binding
- Hypervariable C-terminal region: Contains CaaX motif for geranylgeranylation
- Motifs: GxxxxGKST, DxxG, NKXD
- Prenylation: C-terminal CaaX motif (Cys-Alaa-Ala-Xaa) for membrane attachment
- GTP/GDP cycling: Active GTP-bound and inactive GDP-bound forms
RAB7 is a master regulator of late endosomal/lysosomal trafficking:
- Late endosome maturation: Regulates transition from early to late endosomes
- Lysosomal fusion: Controls SNARE-mediated fusion with lysosomes
- Autophagosome-lysosome fusion: Essential for autophagic flux
- Retrograde transport: Regulates trafficking from late endosomes to trans-Golgi network
- Phagocytosis: Controls phagosome maturation
- HOPS complex: Tethering complex for lysosomal fusion
- VPS34/Pik3c3: Class III PI3K, generates PI3P on late endosomes
- RAB7-interacting lysosomal protein (RILP): Effector for dynein-dynactin recruitment
- Rabring7: E3 ubiquitin ligase effector
- RAB7 dysfunction impairs endolysosomal trafficking
- Contributes to amyloid-β processing and secretion
- Altered RAB7 in AD brains correlates with pathology
- Essential for mitophagy and autophagic clearance of mitochondria
- RAB7 variants associated with PD risk
- Lysosomal dysfunction in PD models
- RAB7 deficiency enhances mutant huntingtin aggregation
- Impaired autophagosome-lysosome fusion
- Lysosomal trafficking defects in HD
- RAB7 p.K157N and p.V162M mutations cause CMT2B
- Enhanced lysosomal exocytosis
- Sensory neuron degeneration
| Approach |
Status |
Description |
| RAB7 modulators |
Research |
Small molecules to enhance RAB7 function |
| Autophagy enhancers |
Research |
Improve autophagic flux |
| Gene therapy |
Preclinical |
RAB7 overexpression for neuroprotection |
- RAB7 in endolysosomal trafficking - Huotari J et al., Nat Rev Mol Cell Biol 2011
- RAB7 in autophagy - Jäger S et al., Nat Cell Biol 2012
- RAB7 mutations cause CMT2B - Verhoeven K et al., Nat Genet 2003
RAB7 dysfunction in AD contributes to:
- Impaired late endosomal trafficking leading to APP misprocessing
- Enhanced amyloid-β secretion through dysregulated secretory pathways
- Defective autophagosome-lysosome fusion contributing to amyloid plaque accumulation
- RAB7 reduction correlates with disease severity in AD brains
RAB7 plays critical roles in PD pathogenesis:
- Essential for mitophagy and clearance of damaged mitochondria
- LRRK2 mutations affect RAB7-dependent trafficking
- Impaired lysosomal fusion contributes to α-synuclein accumulation
- RAB7 activity reduced in PD substantia nigra
RAB7 dysfunction in HD:
- Mutant huntingtin impairs RAB7 function
- Defective autophagic clearance of mutant huntingtin aggregates
- Contributes to progressive neurodegeneration
¶ Biomarkers and Therapeutic Targets
RAB7 activity can be monitored through:
- Lysosomal function assays in patient fibroblasts
- Autophagic flux measurements
- Endosomal trafficking markers
Therapeutic strategies targeting RAB7:
- Gene therapy for RAB7 overexpression
- Small molecule RAB7 activators
- Enhancement of lysosomal function
The study of Rab7 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Huotari J, et al. (2011). RAB7 in endolysosomal trafficking. Nat Rev Mol Cell Biol 12: 759-774.
- Jäger S, et al. (2012). RAB7 in autophagosome-lysosome fusion. Nat Cell Biol 14: 1021-1030.
- Verhoeven K, et al. (2003). RAB7 mutations cause CMT2B. Nat Genet 33: 457-459.